Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switch from Biktarvy to long-acting cabotegravir + rilpivirine every 2 months in virologically suppressed adults with HIV-1
NL-OMON54886Phase 3Completed
- Sponsor
- GSK
- Start
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of cabotegravir, rilpivirine, bictegravir + emtricitabine + tenofovir alafenamide in Human immunodeficiency virus infection type 1, sponsored by GSK. Started Jan 2021; status: completed.
02
Drugs
cabotegravirrilpivirinebictegravir + emtricitabine + tenofovir alafenamide
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on NL-OMON54886.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54886.